Navigation Links
Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress

approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

About GPC Biotech

GPC Biotech AG is a biopharmaceutical company discovering and developing new anticancer drugs. GPC Biotech's lead product candidate -- satraplatin -- has achieved target enrollment in a Phase 3 registrational trial as a second-line chemotherapy treatment in hormone-refractory prostate cancer. The U.S. FDA has granted fast track designation to satraplatin for this indication, and GPC Biotech has completed the rolling NDA submission process for this compound. GPC Biotech is also developing a monoclonal antibody with a novel mechanism-of-action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and has ongoing drug development and discovery programs that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany), and its wholly owned U.S. subsidiary has sites in Waltham, Massachusetts and Princeton, New Jersey. For additional information, please visit GPC Biotech's Web site at http://www.gpc-biotech.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of GPC Biotech AG and Pharmion Corporation, including statements relating to results of the SPARC trial and statements relating to the potential efficacy and safety profile of satraplatin. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or im
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
Post Your Comments:
(Date:7/31/2014)... 2014  Decision Resources Group is launching an extension ... to now include ChinaTrack; the new capabilities track the ... interactive dashboard providing detailed brand-level share tracking and analytics. ... level. Other key capabilities of the new ... addition to end-user surveys of healthcare facilities, ChinaTrack data ...
(Date:7/31/2014)... -- Touro University California,s College of Pharmacy is pleased ... of a $150,000 grant by the Joseph & Vera ... research and classroom space on its campus. ... of health sciences, and will help us apply high-tech ... our students," said Shelley Berkley , CEO and ...
(Date:7/31/2014)... Hovione today announced that its API plant in ... pre-approval inspection by the US Food and Drug Administration (FDA). ... Safety Officer, Ms. Britanny Terhar , lasted 5 days ... concluded on the 25 th . The inspection confirmed the ... Good Manufacturing Practices (GMP) and no Form 483 observations were ...
Breaking Medicine Technology:Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Touro University California Garners Grant From Long Foundation 2Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2
(Date:7/31/2014)... August 01, 2014 The 2013 ... increasing 0.89 points from 75.07 in 2012. The ... tourism-related sectors and integrates them into an overall ... become increasingly more satisfied with Hong Kong over ... consistently excelling in service performance in Hong Kong ...
(Date:7/31/2014)... Ce-Classes.com has announced that they are ... professionals, a Systematic Review of Sexual Satisfaction . ... the International Journal of Clinical and Health Psychology. , ... a need to have accurate information about sexual satisfaction ... possible. The material provides a systematic review of ...
(Date:7/31/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
(Date:7/31/2014)... Weblify has finally been released by marketing and advertising ... The result is a perfected and fine tuned platform ... minutes without knowing any HTML or other programming languages. , ... SEO expert, agrees that this platform allows anyone to create ... web site builders out there, but this is truly unique. ...
(Date:7/31/2014)... Cosmetic Town is a new web ... consumers considering cosmetic treatments. The site features doctors ... is to educate prospective patients on a variety of ... validated referral system that helps patients find cosmetic specialists ... respective fields. , Cosmetic Town started its recruitment ...
Breaking Medicine News(10 mins):Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 2Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 3Health News:The New Doctors’ Directory, Cosmetic Town Does the Research for Consumers of Plastic Surgeries 2
... 60-year-old drug chloroquine eliminated certain malignancies in mice, researchers ... common anti-malaria drug called chloroquine can also prevent the ... a U.S. study finds. , The finding may help ... , Scientists at The Scripps Institute and St. Jude,s ...
... to protect the heart, can lead to halting of ... News) -- Men undergoing hormone therapy for prostate cancer ... a significantly higher risk of dying, new research suggests. ... to elevate liver-function test levels. The end result is ...
... Therapy that stimulates the hand muscles may help treat ... causes muscles spasms in musicians, according to a study ... Neurology, the medical journal of the American Academy of ... practiced particular complicated movements for years. The muscle spasms ...
... Inc. (Nasdaq: GTIV ), the nation,s leading provider ... it is,scheduled to present from 1:30 p.m. to 2:00 ... JPMorgan Healthcare Conference in San Francisco., The event ... audio web cast,which may be accessed by visiting ...
... Medical,Affiliates, Inc. (OTC Bulletin Board: UCIA) reported that revenue ... from $63,672,000 for,the year ended September 30, 2006, an ... September 30, 2007 was $17,885,000 or 9%,greater than the ... increase in revenues is attributed to the opening of ...
... taken more seriously , , WEDNESDAY, Dec. 26 (HealthDay News) ... person,s risk of having a stroke or developing dementia, ... to previous research linking "mini-strokes" to full-fledged strokes, make ... neurology at Johns Hopkins University School of Medicine. , ...
Cached Medicine News:Health News:Malaria Drug Promising Against Cancer 2Health News:Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients 2Health News:Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients 3Health News:Stimulating muscles may improve musician's dystonia 2Health News:Gentiva(R) Health Services to Present January 8 at JPMorgan Healthcare Conference in San Francisco 2Health News:Gentiva(R) Health Services to Present January 8 at JPMorgan Healthcare Conference in San Francisco 3Health News:UCI Medical Affiliates, Inc. Reports Fiscal Year End Results for September 30, 2007 2Health News:UCI Medical Affiliates, Inc. Reports Fiscal Year End Results for September 30, 2007 3Health News:Temporary Amnesia, Confusion Raise Stroke, Dementia Risk 2Health News:Temporary Amnesia, Confusion Raise Stroke, Dementia Risk 3
... to 10 inches/ 25 cm thinner than other benchtop ... X-22 Series is the space-saving multipurpose solution for your ... 46 cm wide • 11 Rotor Library • Achieve ... to Spin 1.5 mL & PCR+ Tubes: 24-place ...
... purpose centrifuges offer high-volume versatility along with ... making them ideal for a wide variety ... Four- or six-place sealed swinging bucket ... rotors offered , Lare capacity (4 x ...
... designed to accommodate over 55 centrifuge tubes, ... heat labile samples. Incorporating the latest technology, ... automatic quick cooling from 22 C to ... maintenance brushless motor, low pitch 62 dBA ...
Inquire...
Medicine Products: